Fate Therapeutics(FATE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

FATE Fate Therapeutics

Market Closed 11-06 16:00:00 EST

1.84

-0.01

-0.81%

盘后1.82

-0.02-0.93%

19:30 EST

High1.95	Low1.81	Vol1.86M
Open1.85	D1 Closing1.85	Amplitude7.57%
Mkt Cap223.08M	Tradable Cap195.78M	Total Shares121.57M
T/O3.49M	T/O Rate1.75%	Tradable Shares106.69M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"FATE","market":"US","secType":"STK","nameCN":"Fate Therapeutics","latestPrice":1.835,"timestamp":1793998800000,"preClose":1.85,"halted":0,"volume":1862248,"hourTrading":{"tag":"盘后","latestPrice":1.818,"preClose":1.835,"latestTime":"19:30 EST","volume":8413,"amount":15390.968,"timestamp":1794011403528,"change":-0.017,"changeRate":-0.009264,"amplitude":0.016185},"delay":0,"changeRate":-0.008108108108108174,"floatShares":106690845,"shares":121568800,"eps":-1.052849,"marketStatus":"Market Closed","change":-0.015,"latestTime":"11-06 16:00:00 EST","open":1.85,"high":1.95,"low":1.81,"amount":3487214.5052584,"amplitude":0.075676,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-1.052849,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1794214800000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1380600000000,"exchange":"NASDAQ","adjPreClose":1.85,"preHourTrading":{"tag":"盘前","latestPrice":1.8768,"preClose":1.85,"latestTime":"08:53 EST","volume":1347,"amount":2552.8719813000002,"timestamp":1793973192977,"change":0.0268,"changeRate":0.014486,"amplitude":0.087622},"postHourTrading":{"tag":"盘后","latestPrice":1.818,"preClose":1.835,"latestTime":"19:30 EST","volume":8413,"amount":15390.968,"timestamp":1794011403528,"change":-0.017,"changeRate":-0.009264,"amplitude":0.016185},"volumeRatio":1.3804993004121822,"impliedVol":1.1839,"impliedVolPercentile":0.5976},"requestUrl":"/m/hq/s/FATE","defaultTab":"news","newsList":[{"id":"2681885135","title":"Revelation Biosciences Q3 Net Loss Widens on Gemini Development Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2681885135","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681885135?lang=en_us&edition=fundamental","pubTime":"2026-11-06 06:38","pubTimestamp":1793918290,"startTime":"0","endTime":"0","summary":"Revelation Biosciences Q3 net loss widens on Gemini development costsOverviewUS clinical-stage life sciences firm's Q3 net loss widened year-over-yearCompany ended Q3 with $9.1 mln in cash, expects fu","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261105:nL2N46M1S2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VTVT","BK4139","DWTX","FATE","REVB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681288379","title":"Fate Therapeutics Enters $100 Million At-the-Market Stock Offering Agreement with Leerink Partners","url":"https://stock-news.laohu8.com/highlight/detail?id=2681288379","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681288379?lang=en_us&edition=fundamental","pubTime":"2026-11-06 06:16","pubTimestamp":1793916971,"startTime":"0","endTime":"0","summary":"Fate Therapeutics Enters $100 Million At-the-Market Stock Offering Agreement With Leerink PartnersFate Therapeutics established an at-the-market offering program of up to $100 million in common stock ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261105:nNDLhGJkV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MNSH","BK4207","FATE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681883998","title":"Rezolute Q1 Loss Widens Slightly; Sees Phase 3 Tumor HI Data by Mid-Dec 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2681883998","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681883998?lang=en_us&edition=fundamental","pubTime":"2026-11-06 06:08","pubTimestamp":1793916537,"startTime":"0","endTime":"0","summary":"Rezolute Q1 loss widens slightly; sees Phase 3 tumor HI data by mid-Dec 2026OverviewMetabolic disease company's fiscal Q1 net loss widened slightly from a year agoOperating expenses declined slightly,","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261105:nL2N46M1KX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRDA","BK4139","RZLT","FATE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681888728","title":"Organogenesis Q3 Revenue Drops 70% on Lower Wound Care Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2681888728","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681888728?lang=en_us&edition=fundamental","pubTime":"2026-11-06 06:00","pubTimestamp":1793916015,"startTime":"0","endTime":"0","summary":"Organogenesis Q3 revenue drops 70% on lower wound care salesOverviewRegenerative medicine firm's Q3 revenue fell 70% yr/yr, driven by lower wound care salesCompany posted a Q3 net loss versus a profit","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261105:nL2N46M1JL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["URGN","BK4139","ORGO","FATE","PYXS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681409888","title":"Caribou Biosciences Q3 Revenue Declines, to Discontinue Lead Clinical Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2681409888","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681409888?lang=en_us&edition=fundamental","pubTime":"2026-11-06 05:55","pubTimestamp":1793915758,"startTime":"0","endTime":"0","summary":"Caribou Biosciences Q3 revenue declines, to discontinue lead clinical programOverviewUS genome-editing biopharma's Q3 revenue fell yr/yr, net loss narrowed slightlyCompany to discontinue lead clinical","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261105:nL2N46M1KK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRDA","CRBU","RNAC","FATE","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681888413","title":"CAMP4 Therapeutics Q3 Loss Per Share Misses Analyst Expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2681888413","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681888413?lang=en_us&edition=fundamental","pubTime":"2026-11-06 05:53","pubTimestamp":1793915621,"startTime":"0","endTime":"0","summary":"CAMP4 Therapeutics Q3 loss per share misses analyst expectationsOverviewUS biopharma firm's Q3 loss per share missed analyst expectationsQ3 net loss widened, mainly due to non-cash loss from derivativ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261105:nL2N46M1JK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PYXS","CAMP","BK4139","FATE","BK4020","TRDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681888637","title":"Fate Therapeutics - Registration Statement Covers Offering of Securities up to $300 Mln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2681888637","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681888637?lang=en_us&edition=fundamental","pubTime":"2026-11-06 05:48","pubTimestamp":1793915305,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261105:nFWN46M3YG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FATE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681630888","title":"Fate Therapeutics - Sales Agreement Prospectus Covers up to $100 Mln Common Stock with Leerink Partners - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2681630888","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681630888?lang=en_us&edition=fundamental","pubTime":"2026-11-06 05:48","pubTimestamp":1793915305,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261105:nFWN46M3YG:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","FATE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681000244","title":"Janux Therapeutics Q3 Net Loss Narrows on Lower R&D Expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2681000244","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681000244?lang=en_us&edition=fundamental","pubTime":"2026-11-06 05:37","pubTimestamp":1793914648,"startTime":"0","endTime":"0","summary":"Janux Therapeutics Q3 net loss narrows on lower R&D expensesOverviewUS biopharma firm's Q3 collaboration revenue declined yr/yrQ3 net loss narrowed from prior yearFirst patient dosed in Phase 1 JANX01","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261105:nL2N46M1GY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FATE","JANX","TRDA","BK4539","PYXS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681007309","title":"aTyr Pharma Q3 Net Loss Narrows as Expenses Fall","url":"https://stock-news.laohu8.com/highlight/detail?id=2681007309","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681007309?lang=en_us&edition=fundamental","pubTime":"2026-11-06 05:16","pubTimestamp":1793913398,"startTime":"0","endTime":"0","summary":"Ethos Technologies Q3 net loss narrows as expenses fallOverviewUS biotech firm's Q3 revenue was zero; net loss narrowed from prior yearOperating expenses in Q3 fell year-over-year, mainly due to...","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261105:nL2N46M1G4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4173","FATE","BK4139","ATYR","BK4563","LIFE","RNAC","PYXS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681100734","title":"Celcuity Q3 Loss Widens on Revtorpyk Commercialization Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2681100734","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681100734?lang=en_us&edition=fundamental","pubTime":"2026-11-06 05:16","pubTimestamp":1793913395,"startTime":"0","endTime":"0","summary":"Celcuity Q3 loss widens on REVTORPYK commercialization costsOverviewUS biotechnology firm's Q3 saw no product revenue as REVTORPYK shipments began at quarter-endAdjusted net loss and adjusted loss per","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261105:nL2N46M1GT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4505","BK4588","CELC","DYN","FATE","TRDA","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681002144","title":"Verastem Q3 Adjusted Loss Widens on Increased R&D Expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2681002144","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681002144?lang=en_us&edition=fundamental","pubTime":"2026-11-06 05:12","pubTimestamp":1793913128,"startTime":"0","endTime":"0","summary":"Verastem Q3 adjusted loss widens on increased R&D expensesOverviewUS biopharma firm's Q3 net product revenue more than doubled yr/yr to $24 mlnAdjusted loss per share for Q3 missed analyst expectation","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261105:nL2N46M1FW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","TRDA","BK4139","FATE","BK4585","DYN","VSTM","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681002191","title":"Voyager Therapeutics Q3 Collaboration Revenue Drops, Net Loss Narrows","url":"https://stock-news.laohu8.com/highlight/detail?id=2681002191","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681002191?lang=en_us&edition=fundamental","pubTime":"2026-11-06 05:11","pubTimestamp":1793913066,"startTime":"0","endTime":"0","summary":"Voyager Therapeutics Q3 collaboration revenue drops, net loss narrowsOverviewUS biotech firm's Q3 collaboration revenue fell sharply yr/yr as Neurocrine partnership shifted phasesQ3 net loss narrowed ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261105:nL2N46M1GM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0154245673.USD","LU0154245756.USD","BK4139","LU2324357040.USD","TRDA","NBIX","LU0320765992.SGD","LU0889565916.HKD","LU2065171311.SGD","FATE","LU2065171402.SGD","LU2065169927.USD","VYGR","LU0109394709.USD","LU2065170008.USD","LU0823416689.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681027373","title":"Fate Therapeutics Q3 2026 Net Loss Narrows Year over Year to $30.69 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2681027373","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681027373?lang=en_us&edition=fundamental","pubTime":"2026-11-05 20:18","pubTimestamp":1793881137,"startTime":"0","endTime":"0","summary":"Fate Therapeutics Q3 2026 net loss narrows year over year to $30.69 millionFate Therapeutics’ third-quarter 2026 net loss narrowed year over year to $30.69 million.There was no collaboration revenue, ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261105:nNDL4gPWXz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","NDAQ","IE00B3QW5Z07.USD","IE00BQXX3D17.EUR","SG9999014039.USD","SG9999014021.USD","IE00BN0W2V16.EUR","SG9999014005.SGD","LU2095319765.USD","SG9999014013.SGD","IE00BN0W2W23.USD","BK4588","LU0314104364.USD","IE00BKPKM429.USD","BK4139","BK4585","IE00B64PRP62.GBP","IE00BN0W2T93.GBP","BK4112","FATE","IE00BQXX3C00.GBP","LU2210150020.SGD","IE00BQXX3F31.USD","BCDF","LU2210149790.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681702760","title":"Fate Therapeutics - Reports $139.10 Mln Cash, Cash Equivalents, Investments; Cash Runway to Mid-2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2681702760","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681702760?lang=en_us&edition=fundamental","pubTime":"2026-11-05 20:00","pubTimestamp":1793880014,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261105:nTUA99NQJF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FATE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681024294","title":"Fate Therapeutics Q3 Basic EPS USD -0.25","url":"https://stock-news.laohu8.com/highlight/detail?id=2681024294","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681024294?lang=en_us&edition=fundamental","pubTime":"2026-11-05 20:00","pubTimestamp":1793880014,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261105:nPLXWQ9T6F:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","FATE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680777039","title":"Fate Therapeutics Grants New Hires 300,000 Stock Options, 87,000 Restricted Stock Units","url":"https://stock-news.laohu8.com/highlight/detail?id=2680777039","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680777039?lang=en_us&edition=fundamental","pubTime":"2026-11-04 05:20","pubTimestamp":1793740813,"startTime":"0","endTime":"0","summary":"Fate Therapeutics Grants New Hires 300,000 Stock Options, 87,000 Restricted Stock UnitsFate Therapeutics granted non-qualified stock options covering 300,000 shares to one newly hired non-executive em","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261103:nNDL26JTNy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00BGHQF748.EUR","IE00BQXX3C00.GBP","IE00BQXX3D17.EUR","IE00B64PRP62.GBP","SG9999014005.SGD","BCDF","FATE","SG9999014039.USD","IE00B3QW5Z07.USD","SG9999014013.SGD","SG9999014021.USD","LU2095319765.USD","IE00BN0W2T93.GBP","LU2210149790.SGD","LU0314104364.USD","NDAQ","BK4112","BK4585","IE00BN0W2V16.EUR","BK4139","IE00BKPKM429.USD","IE00BN0W2W23.USD","IE00BQXX3F31.USD","LU2210150020.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680724607","title":"Fate Therapeutics Reports New Employee Inducement Awards Under NASDAQ Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2680724607","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680724607?lang=en_us&edition=fundamental","pubTime":"2026-11-04 05:05","pubTimestamp":1793739905,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261103:nTUABTFLPQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FATE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680377782","title":"Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2680377782","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680377782?lang=en_us&edition=fundamental","pubTime":"2026-11-04 05:05","pubTimestamp":1793739900,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Nov.  03, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative and broadly accessible pipeline ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/11/03/3394789/24675/en/fate-therapeutics-reports-new-employee-inducement-awards-under-nasdaq-listing-rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LCLG","LENZ","BK4139","BK4007","FATE","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678106523","title":"Wedbush Remains a Buy on Fate Therapeutics (FATE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2678106523","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678106523?lang=en_us&edition=fundamental","pubTime":"2026-10-27 22:26","pubTimestamp":1793111216,"startTime":"0","endTime":"0","summary":"Wedbush analyst maintained a Buy rating on Fate Therapeutics today and set a price target of $7.00. In a report released yesterday, Piper Sandler a...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wedbush-remains-a-buy-on-fate-therapeutics-fate-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wedbush-remains-a-buy-on-fate-therapeutics-fate-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FATE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.fatetherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.1178},{"period":"1month","weight":-0.1465},{"period":"3month","weight":-0.3446},{"period":"6month","weight":-0.2322},{"period":"1year","weight":0.7644},{"period":"ytd","weight":0.8675}],"compareEarnings":[{"period":"1week","weight":-0.027},{"period":"1month","weight":-0.0539},{"period":"3month","weight":-0.0491},{"period":"6month","weight":-0.0032},{"period":"1year","weight":0.0969},{"period":"ytd","weight":0.0783}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma and FT522, to treat lymphoma and autoimmune disorders; and CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.538462,"avgChangeRate":0.049458},{"month":2,"riseRate":0.615385,"avgChangeRate":0.078089},{"month":3,"riseRate":0.461538,"avgChangeRate":-0.020579},{"month":4,"riseRate":0.615385,"avgChangeRate":0.004138},{"month":5,"riseRate":0.461538,"avgChangeRate":0.079338},{"month":6,"riseRate":0.461538,"avgChangeRate":-0.000833},{"month":7,"riseRate":0.384615,"avgChangeRate":0.039214},{"month":8,"riseRate":0.307692,"avgChangeRate":-0.024594},{"month":9,"riseRate":0.384615,"avgChangeRate":0.000021},{"month":10,"riseRate":0.230769,"avgChangeRate":-0.093969},{"month":11,"riseRate":0.5,"avgChangeRate":0.075928},{"month":12,"riseRate":0.538462,"avgChangeRate":0.045045}],"exchange":"NASDAQ","name":"Fate Therapeutics","nameEN":"Fate Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Fate Therapeutics(FATE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Fate Therapeutics(FATE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Fate Therapeutics,FATE,Fate Therapeutics股票,Fate Therapeutics股票老虎,Fate Therapeutics股票老虎国际,Fate Therapeutics行情,Fate Therapeutics股票行情,Fate Therapeutics股价,Fate Therapeutics股市,Fate Therapeutics股票价格,Fate Therapeutics股票交易,Fate Therapeutics股票购买,Fate Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Fate Therapeutics(FATE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Fate Therapeutics(FATE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}